Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of a Combined RSV/hMPV/PIV3 Vaccine Candidate in Adults Aged 60 Years and Older
NCT06604767Phase 1Completed
- Sponsor
- Sanofi
- Start
- Sep 2024
- Primary completion
- Mar 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of RSV/hMPV/PIV3 formulation 1 in respiratory syncytial virus infection (RSV), human metapneumovirus infection (HMPV) and parainfluenza virus infection (9 arms), sponsored by Sanofi. Primary endpoints: Presence of unsolicited systemic adverse events at 30 minutes, Presence of solicited administration site reactions at 7 days and 8 more. Started Sep 2024; status: completed.
02
Drugs
RSV/hMPV/PIV3 formulation 1
03
Conditions
respiratory syncytial virus infection (RSV)human metapneumovirus infection (HMPV)parainfluenza virus infection
Beyond the preview
Go deeper on NCT06604767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06604767.